Use of 3-methyl adenine in preparing medicament for treating neurodegenerative disease

A neurodegenerative, methyladenine technology, applied in the direction of nervous system diseases, drug combinations, active ingredients of heterocyclic compounds, etc.

Inactive Publication Date: 2009-05-20
SUN YAT SEN UNIV
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Looking at domestic and foreign patent documents, there is no experimental result of 3-methyladenine inhibiting the DRG axon degeneration model, and there is no research on the effect of 3-methyladenine on the behavior of Alzheimer's disease transgenic animal models. improved research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of 3-methyl adenine in preparing medicament for treating neurodegenerative disease
  • Use of 3-methyl adenine in preparing medicament for treating neurodegenerative disease
  • Use of 3-methyl adenine in preparing medicament for treating neurodegenerative disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1 Protection of Wallerian Axonal Degeneration Model with 3-Methyladenine

[0017] DRG ganglia isolated from E16 rat embryos were cultured in medium containing fluorodeoxyuridine and uracil to remove non-neural cells. After 5 days of in vitro culture, the axons grew longer, and the ganglion was cut along the periphery of the ganglion with a micro scalpel, and then the ganglion was removed, leaving only axons without cell bodies on the culture dish. Under normal circumstances, the axons of the neurons with the cell body removed begin to break and drop in shape after 4-6 hours, and degrade and disappear in about 12 hours. The inventors added 3-methyladenine 3 hours before removing the ganglion, and checked under a microscope whether the compound had a protective effect on neurodegeneration 12 hours after removing the ganglion. The intensity of the protective effect on axons was judged by the following quantitative method.

[0018] The quantitative analysis of axo...

Embodiment 2

[0020] Example 2 The effect of 3-methyladenine on the behavior of model mice was detected by using a transgenic animal model of Alzheimer's disease.

[0021] Ten 8-month-old male mice of Alzheimer's disease transgenic animal model mice were randomly divided into a 3-methyladenine group (5 mice) and a control group (5 mice). The 3-methyladenine group was injected intraperitoneally with 150 mg / kg 3-methyladenine saline solution, and the control group was injected with normal saline, once every two days for 3 months. One week after the last injection, the behavioral indicators of each group of animals from the control mouse group injected with normal saline and the model group injected with 3-methyladenine were observed correspondingly, including platform jumping test and water maze test.

[0022] Platform jump test results:

[0023] Put the animal on the high platform in the experimental apparatus, electrify (AC38V) on the bottom grid, and record the number of times the mouse jum...

Embodiment 3

[0030] Example 3 Preparation of 3-methyladenine injection

[0031] Formula: 3-Methyladenine 5g

[0032] Sodium chloride 10g

[0033] Distilled water up to 1000ml

[0034] Operation method: Dissolve the drug with physiological saline to form a solution containing 5 mg or 10 mg of 3-methyladenine per ml, and make water for injection of 5 mg or 10 mg per bottle according to the GMP requirements and the usual preparation method for water injections Injection, the finished product can be obtained after passing the quality appraisal.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of 3-methyl adenine in preparation of a medicine used for treating neurodegenerative diseases. Through a great number of researches, the invention discovers that the 3-methyl adenine can be used as an active ingredient for treating the neurodegenerative diseases, such as Alzheimer diseases, parkinson diseases, spinal cord injuries, diabetes peripheral neuritis, ischemic cerebrovascular diseases (cerebral infarction, cerebral hemorrhage and the like). The 3-methyl adenine in the invention has excellent treatment effect and wide application prospect.

Description

technical field [0001] The present invention relates to 3-methyladenine, in particular, relates to a new medicinal application of 3-methyladenine. Background technique [0002] Neurodegenerative disease (Neurodegenerative disease, NDD) is one of the most common diseases of the nervous system, including Alzheimer's disease (Alzheimer's Disease, AD), Parkinson's disease (Parkinson's Disease, PD), amyotrophic lateral sclerosis (amyotrophic lateral sclerosis, ALS) and Huntington's disease (Huntington disease, HD) and so on. Among them, Alzheimer's disease and Parkinson's disease have extremely high incidence rates in the elderly over 65 years old, reaching about 10% and 1-2% respectively (Martin CR et al.2002). A recent survey in China found that the incidence of Parkinson's disease among the elderly over 65 years old was 1.7%, which is close to that of developed countries. The onset of most neurodegenerative diseases is slow, and the course of general neurodegenerative diseas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/52A61P25/14A61P25/28
Inventor 蒋嵩山孔祥复
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap